Senior executives begin a run of November investor events this week, with the shares having rallied firmly since the group reset its strategy in August.

Oxford Nanopore Technologies (LSE:ONT) is set for a busy month of investor engagement. The company said on 4 November that finance chief Nick Keher would take part in a fireside chat at a healthcare conference in New York on 10 November, followed by a MedTech and diagnostics forum on 11 November. Chief executive Francis Van Parys will present at a global healthcare conference in London on 17 November, and both will appear at a European investor conference in Windsor on 30 November.

The appearances come without any new financial update, and the most recent detailed figures remain the first-half results published on 19 August. Even so, the company has been among the best performers in the mid-cap index, ranking first in the FTSE 250 since the start of August.

About the company

Oxford Nanopore Technologies develops and sells DNA and RNA sequencing technology, based on a method that passes molecules through tiny protein pores and reads the changes in electrical current. Its devices range from small portable sequencers to large high-throughput systems, and they can read very long stretches of genetic material in real time. Customers include academic and government laboratories, pharmaceutical and biotechnology companies, and a growing number of clinical and public health users.

The company earns money from selling instruments and, more importantly, from recurring sales of consumables, including the flow cells that are used in each sequencing run. Because consumables reflect how often customers use their installed devices, they act as a gauge of adoption. The Business is still investing heavily in product development and commercial expansion, and its stated goal is to reach breakeven and then positive free Cash Flow as Revenue scales.

In the first half, revenue rose 12.3% at constant currency to £116.7m, gross Margin increased to 62.2% and the adjusted EBITDA loss narrowed to £22.1m from £48.3m. Net cash and liquid investments were £234.5m with no debt. Full-year guidance remains at 16% to 20% constant-currency revenue growth, and new targets call for revenue above $700m by 2030.

Recovery from a difficult reset

The August results were a catalyst, with the shares reported to have jumped about 16% in early trading. Revenue for the six months rose 12.3% at constant currency to £116.7m, while gross margin improved by 400 basis points to 62.2%. The adjusted EBITDA loss more than halved to £22.1m from £48.3m, helped by a 7% reduction in adjusted operating expenses.

That revenue performance was below management's expectations, reflecting weakness in China, where sales fell by about 16%, and in the Middle East, down about 14%. Device sales were solid, up 32.6%, but consumables rose just 2.7%, a gap that bears watching because consumables tend to reflect how intensively customers use installed instruments.

Management left its full-year guidance unchanged at 16% to 20% constant-currency revenue growth, with gross margin of about 62% and adjusted operating expenses down 2% to flat. Reaching the guided range implies a marked acceleration in the second half, likely to be a central topic for investors at the upcoming events. A post-period cross-licensing agreement with a diagnostics company, including a $20m upfront payment expected in the second half, should provide some assistance.

Where sequencing technology is heading

Genomic sequencing is expanding beyond pure academic study into areas such as cancer, rare disease, infectious disease surveillance and pharmaceutical development. Long-read approaches are valued for detecting complex genetic variation that shorter reads can miss, and for real-time analysis.

Competition is significant, with several established technology providers vying for the same customers, and adoption depends on cost per sample, accuracy, ease of use and regulatory approvals for clinical applications.

What to watch next

The conference appearances this month may give management an opportunity to discuss progress against guidance, particularly the second-half acceleration needed to reach the full-year revenue range. Consumables growth, the performance of China and the Middle East, and the receipt of the upfront payment from the licensing agreement are all relevant.

Beyond the near term, investors will follow Operating Expense control, progress towards EBITDA breakeven in 2027 and the development of clinical partnerships. The next full set of figures will show whether the strategic reset is turning into more consistent growth.

Targets for 2030

Alongside the results, Van Parys set out four strategic priorities: customer-centric growth, focused innovation, disciplined execution and a high-performance culture. The company (LSE:ONT) is prioritising whole-genome sequencing for academic and discovery work, biopharma and selected clinical applications, and management acknowledged that the group had not been converting its technological strengths into adoption and growth at the level it should.

New targets call for more than $700m of revenue by 2030 and an adjusted EBITDA margin above 15%. Before then, the company is aiming for adjusted EBITDA breakeven in 2027 and positive free cash flow in 2028.

The Balance Sheet gives some room to pursue that plan. Net cash and liquid investments stood at £234.5m at the half year, with no debt, although the total had fallen by about £68m to £70m from the year end, which the company (LSE:ONT) linked to seasonal Working Capital outflows and one-off items.

Other recent developments have included an agreement to integrate the company's sequencing technology into MyOme's rare disease platform, and appointments in medical and Marketing Leadership intended to strengthen regulatory, commercial and market development capabilities. Performance by region has been uneven, with Europe, the Middle East, Africa and India identified as an area of strength and Asia Pacific, especially China, as the weak spot.

The conference appearances offer the most immediate opportunity for investors to hear management's assessment of second-half progress against guidance.